290-POS

Objectives Endothelial dysfunction is thought to be one of the mechanism involving in pre-eclampsia manifestation. Likewise, one of the inflammatory mediators involved in this process is interleukin (IL)-6, a mediator synthesized by mononuclear phagocytes, endothelial cells and fibroblasts in response to inflammatory stimuli. IL-6 has been described increased in women with pre-eclampsia. Thus, we aimed to investigate the association between endothelial dysfunction (by flow-mediated dilatation) and IL-6 levels in women with pre-eclampsia. Methods Following ethical approval, a written consent was obtained from 21 women diagnosed with pre-eclampsia. Endothelial function was evaluated by brachial artery flow-mediated dilatation. IL-6 was quantified using MagPlexTH-C - microspheres system, in maternal plasma. Pre-eclamptic groups was divided into altered (n = 9) and normal (n = 12) endothelial function, considering a cutoff point of 10%, below or above, respectively. The Mann–Whitney U-tests was carried out to compare the IL-6 values between pre-eclamptic groups. Correlations between the parameters were tested with a Spearman’s Rank correlation tests. The null hypothesis was rejected when p Results Higher levels of IL-6 was observed in altered flow-mediated dilatation test group in relation to normal endothelial group (median [IQR]): 4.34 pg/mL [3.38; 6.22] and 2.56 pg/mL [1.57; 3.67]; p = 0.028, respectively. When an analysis was made between flow-mediated dilatation levels and IL-6, a negative correlation was found (r = −0.514, p = 0.017). Conclusions As expected in patients with pre-eclampsia, a high inflammatory response showed a low flow-mediated dilatation. The significant correlation between a potential clinical prediction method and a well-known inflammatory cytokine support the importance of working not only with one potential biomarker to predict pre-eclampsia, but also, with a group of molecules and/or techniques, in order to increase the chance to diagnose the disease as early in pregnancy as possible – before signals and symptoms. Disclosures M.R. Hentschke: None. M.C. Vieira: None. E.V. da Cunha Filho: None. J. Guaragna: None. C.E. Poli de Figueiredo: None. B.E. Pinheiro da Costa: None.